<DOC>
	<DOCNO>NCT01254422</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity Phase III lot CYD dengue vaccine pediatric population Malaysia . Primary Objectives : - To describe safety ( term solicit unsolicited adverse event ) CYD dengue vaccine subject dose . - To describe antibody response dengue virus serotype post-Dose 2 post-Dose 3</brief_summary>
	<brief_title>Study Tetravalent Dengue Vaccine Healthy Children Aged 2 11 Years Malaysia</brief_title>
	<detailed_description>Healthy participant age 2 11 year receive 3 vaccination pre-determined schedule followed-up least 6 month last vaccination .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 2 11 year day inclusion Assent form sign date subject ( subject â‰¥ 7 year ) inform consent form sign dated parent ( ) another legally acceptable representative , independent witness two parent legally acceptable representative illiterate Subject parent/legally acceptable representative able attend schedule visit comply trial procedure Subject good health , base medical history physical examination For female subject childbearing potential , use effective method contraception abstinence least 4 week prior first vaccination , least 4 week last vaccination Known pregnancy , positive urine pregnancy test ( female subject childbearing potential ) Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Planned receipt vaccine 4 week follow trial first vaccination , except pandemic influenza vaccination receipt blood bloodderived product past 3 month , might interfere assessment immune response Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Seropositivity human immunodeficiency virus ( HIV ) report parent/legally acceptable representative Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine ( ) use trial vaccine contain substance Chronic illness , opinion investigator , stage might interfere trial conduct completion Subjects plan move another country/region within 18 coming month Identified child ( adopted natural ) Investigator site employee Investigator study center , direct involvement propose study study direction Investigator study center .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Dengue fever</keyword>
	<keyword>Dengue hemorrhagic fever</keyword>
	<keyword>CYD dengue vaccine</keyword>
</DOC>